# AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management

> **NCT06376851** · — · ACTIVE_NOT_RECRUITING · sponsor: **HeartFlow, Inc.** · enrollment: 20000 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DIAGNOSTIC_TEST:** AI-enabled quantitative coronary plaque analysis (AI-QCPA)

## Key facts

- **NCT ID:** NCT06376851
- **Lead sponsor:** HeartFlow, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2026-03-27
- **Final completion:** 2030-03-27
- **Target enrollment:** 20000 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06376851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06376851, "AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06376851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*